This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Role of ITGAM in Systemic Lupus Erythematosus

This study has been completed.
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Northwell Health Identifier:
First received: October 27, 2010
Last updated: July 29, 2013
Last verified: July 2013
Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.

Systemic Lupus Erythematosus

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: TAP0307.6: Sub-study of TAP 0307- Enrollment of Normal Controls to Study the Role of ITGAM in Systemic Lupus Erythematosus

Resource links provided by NLM:

Further study details as provided by Northwell Health:

Biospecimen Retention:   Samples With DNA
Blood and DNA will be collected and retained

Enrollment: 40
Study Start Date: December 2009
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Normal Control Subjects with genotype of interest registered in the Genotype and Phenotype Registry

Inclusion Criteria:

  • males and females, age 18 or older, enrolled in Genotype and Phenotype Registry, in general good health
  • Participants who carry the genotype of interest, based on a buccal or blood derived DNA sample

Exclusion Criteria:

  • History of Systemic Lupus Erythematosus, rheumatoid arthritis, or other autoimmune disease
  • History of cancer or lymphoma
  • Current use of aspirin, prednisone, or NSAID or any immunosuppressant
  • Self reported HIV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01230112

United States, New York
Feinstein Institute for Medical Research
Manhasset, New York, United States, 11030
Sponsors and Collaborators
Northwell Health
National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

Responsible Party: Northwell Health Identifier: NCT01230112     History of Changes
Other Study ID Numbers: 09-289
Study First Received: October 27, 2010
Last Updated: July 29, 2013

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on September 21, 2017